New York State Teachers Retirement System Purchases 20,008 Shares of Exelixis, Inc. (NASDAQ:EXEL)

New York State Teachers Retirement System increased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 439,222 shares of the biotechnology company's stock after purchasing an additional 20,008 shares during the period. New York State Teachers Retirement System owned about 0.14% of Exelixis worth $11,398,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new position in Exelixis in the 3rd quarter worth approximately $30,000. Park Place Capital Corp acquired a new position in Exelixis in the 2nd quarter worth approximately $45,000. GAMMA Investing LLC boosted its stake in Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC boosted its stake in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,746 shares during the period. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Exelixis during the 3rd quarter valued at $74,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Maria C. Freire sold 8,250 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the sale, the director now directly owns 91,007 shares in the company, valued at $2,417,145.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Maria C. Freire sold 8,250 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total transaction of $219,120.00. Following the completion of the transaction, the director now owns 91,007 shares of the company's stock, valued at approximately $2,417,145.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dana Aftab sold 1,162 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares of the company's stock, valued at $15,666,873. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 354,020 shares of company stock worth $9,386,366 over the last ninety days. Company insiders own 2.85% of the company's stock.

Exelixis Stock Up 2.8 %

EXEL stock traded up $0.92 during mid-day trading on Friday, reaching $34.12. 4,537,149 shares of the stock traded hands, compared to its average volume of 2,454,909. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $34.45. The business has a 50-day moving average of $27.13 and a two-hundred day moving average of $24.30. The firm has a market capitalization of $9.74 billion, a PE ratio of 21.87, a P/E/G ratio of 0.89 and a beta of 0.51.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to analysts' expectations of $490.31 million. During the same period in the prior year, the company earned $0.10 earnings per share. The business's quarterly revenue was up 14.3% compared to the same quarter last year. On average, equities research analysts anticipate that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EXEL shares. Guggenheim lifted their target price on shares of Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday. StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 13th. Bank of America lifted their target price on shares of Exelixis from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, October 15th. JMP Securities reissued a "market outperform" rating and set a $29.00 target price on shares of Exelixis in a research note on Friday, October 11th. Finally, TD Cowen lifted their target price on shares of Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Exelixis currently has an average rating of "Moderate Buy" and an average price target of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.